Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 12/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | HTR1D | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B | P28222 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238410 | 0.91 | MPO (1.00) | MPOGPR84SLC6A4 | |
| SCHEMBL6971576 | 0.90 | MPO (0.92) | MPOGPR84SLC6A4 | |
| SCHEMBL11992509 | 0.88 | MPO (0.78) | MPOKMT2AKDM4EMEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL21546035 | 0.86 | MPO (0.76) | MPOKMT2AKDM4EMEN1CYP2D6 | |
| SCHEMBL2405001 | 0.85 | MPO (1.00) | MPONOTUMMTNR1AMTNR1BSLC6A4 | |
| SCHEMBL14036644 | 0.84 | MPO (0.72) | MPOKMT2AHTR2CGPR84SLC6A4 | |
| SCHEMBL2403826 | 0.84 | MPO (1.00) | MPONOTUMMTNR1AMTNR1BSLC6A4 | |
| SCHEMBL2404826 | 0.84 | MPO (0.72) | MPOKMT2AHTR2CNOTUMMTNR1A | |
| SCHEMBL4303662 | 0.83 | KDM4E (0.70) | MPOKMT2AKDM4EMEN1CYP2D6 | |
| Iodide SCHEMBL30672192 | 0.82 | MPO (0.70) | MPOKMT2AHTR2CNOTUMMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0580633-B1 | HETEROCYCLIC AMINES USEFUL IN THE THERAPY OF ASTHMA AND INFLAMMATION OF THE RESPIRATORY TRACT | BOEHRINGER MANNHEIM ITALIA (IT) | 1998-06-17 | — | — | EP | claimed |
| CN-117957211-A | Fluorinated tryptamine compounds, analogs thereof, and methods of use thereof | 圣约瑟夫大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023129976-A1 | SALT AND SOLID FORMS OF KETANSERIN | TERRAN BIOSCIENCES, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022256554-A1 | FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | UNIVERSITY OF THE SCIENCES (US) | 2022-12-08 | — | — | WO | disclosed |
| CN-104557664-B | Aromatic heterocyclic derivative and application thereof in medicines | 广东东阳光药业有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-18 | — | — | US | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878733-A1 | Pyrimidine derivatives as ALK-5 inhibitors | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20060292255-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSSANCE HERBS INC. | 2006-12-28 | — | — | US | disclosed |
| US-20060105069-A1 | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | RENAISSANCE HERBS, INC. | 2006-05-18 | — | — | US | disclosed |
| EP-0848706-B1 | SUBSTITUTED BENZENE-FUSED HETEROCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-0848706-A1 | SUBSTITUTED BENZENE-FUSED HETERO- AND CARBOCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5691362-A | ANTIHISTAMINES, BRONCHODILATORS, ANTIINFLAMMATORY AGENTS, GASTROINTESTINAL DISORDERS | SCHERING-PLOUGH CORPORATION (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1996039383-A1 | SUBSTITUTED BENZENE-FUSED HETERO- AND CARBOCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227823-A1 | (E)-4-(3-(3-bromo-4-fluorophenyl)acrylamido)-N-(2-(5-fluoro-1H-indol-3-yl)ethyl)piperidine-4-carboxamide; ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity | CACNA1G, KCNN4, CACNA1E | MPO 2120/4885KMT2A 3432/4885KDM4E 2150/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | MPO 3915/4885KMT2A 253/4885KDM4E 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.